Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QCZ484 in Mild to Moderate Hypertensive Patients
NCT06857955Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2025
- Primary completion
- Sep 2026
- Modality
- RNA Therapeutics
- Countries
- 3
01
Overview
A Phase 2 trial of QCZ484 in hypertension (HTN), sponsored by Novartis. Started Mar 2025; status: active, not recruiting.
02
Drugs
QCZ484
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06857955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06857955.